Morningstar
See the following -
Exorbitant Prices Are Just One Reason to Loathe the Company That Makes the EpiPen
It’s not hard for pharma companies to appear villainous, but Mylan, the maker of the EpiPen, may be in a class by itself. Mylan has drawn the ire of patients, consumer groups and now Congress for raising the price of the device 400% since it acquired EpiPen in 2007. The implement, which delivers life-saving medicine for severe allergy sufferers, can now cost more than $300 per pen. It’s only sold in pairs and must be purchased every year because the drug, epinephrine, loses potency over time. Sales of EpiPen are now in excess of $1 billion annually...
- Login to post comments
Mylan Isn't Alone: 11 Drugmakers with Off-the-Charts Pricing Power
Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor's 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan's, according to a USA TODAY analysis of data from S&P Global Market Intelligence...
- Login to post comments